MedTrace Logo

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

NCT00361257 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2016-02-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of minocycline, an antibiotic, in lessening the decreased mental function sometimes caused by anti-HIV drugs.

Conditions

  • HIV Infections

Interventions

DRUG

Minocycline

Tetracycline antibiotic, 100 mg taken orally every 12 hours

DRUG

Placebo (Tetracycline)

Tetracycline antibiotic placebo, orally every 12 hours

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Neurologic AIDS Research Consortium (NARC)

    collaborator OTHER

  • Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

    lead NETWORK

Principal Investigators

  • Ned Sacktor, MD · Department of Neurology, Johns Hopkins Bayview Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00361257 on ClinicalTrials.gov